Comparison of disease activity, radiographic severity, and disease phenotype according to each single-nucleotide polymorphism (SNP).
| rs688 | rs4420638 | |||||||
|---|---|---|---|---|---|---|---|---|
| Major Allele Homozygotes, n = 211 | Heterozygotes, n = 76 | Minor Allele Homozygotes, n = 14 | p* | Major Allele Homozygotes, n = 222 | Heterozygotes, n = 67 | Minor Allele Homozygotes, n = 13 | p* | |
| Disease activity | ||||||||
| DAS28 | 4.1 (2.9–5.2) | 4.3 (3.0–6.0) | 4.3 (3.5–6.8) | 0.103 | 4.2 (2.9–5.3) | 4.2 (2.9–5.8) | 4.2 (3.3–6.3) | 0.799 |
| Tender joint counts | 3 (1–6) | 4 (1–10) | 6 (1–12) | 0.019 | 3 (1–7) | 4 (1–11) | 4 (1–8) | 0.226 |
| Swollen joint counts | 2 (0–4) | 1 (0–6) | 3 (1–8) | 0.419 | 2 (0–5) | 2 (0–7) | 3 (1–7) | 0.195 |
| ESR, mm/h | 23 (13–38) | 29 (14–58) | 51 (13–62) | 0.005 | 24 (14–39) | 27 (14–39) | 14 (11–50) | 0.728 |
| CRP, mg/dl | 0.2 (0.1–0.8) | 0.4 (0.1–1.7) | 0.5 (0.1–3.3) | 0.008 | 0.3 (0.1–1.2) | 0.2 (0.1–0.8) | 0.5 (0.1–1.9) | 0.267 |
| Radiographic severity | ||||||||
| Total SvdH score | 32 (7–48) | 35 (15–59) | 35 (10–35) | 0.272 | 33 (7–49) | 34 (13–60) | 35 (33–36) | 0.064 |
| Erosion score | 17 (5–24) | 21 (7–30) | 21 (4–24) | 0.243 | 18 (5–25) | 17 (5–31) | 21 (19–23) | 0.456 |
| Narrowing score | 14 (2–24) | 14 (6–26) | 14 (7–15) | 0.428 | 14 (2–24) | 14 (7–26) | 14 (11–16) | 0.439 |
| Disease phenotype | ||||||||
| Duration, yrs | 6 (3–12) | 7 (3–13) | 4 (2–12) | 0.332 | 7 (3–13) | 6 (3–11) | 3 (1–9) | 0.204 |
| RF-positive, n (%) | 143 (67.8) | 56 (73.7) | 10 (71.4) | 0.772 | 151 (68.1) | 49 (73.1) | 9 (69.2) | 0.423 |
| ACPA-positive, n (%) | 157 (74.4) | 58 (76.3) | 11 (78.6) | 0.873 | 162 (73.0) | 54 (80.6) | 10 (76.9) | 0.284 |
↵* For trends of each SNP and after adjustment for age and sex. DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SvdH: Sharp van der Heijde; RF: rheumatoid factor; ACPA: anticitrullinated protein antibody.